

1 **Title:** A code of practice for the Conduct Of Systematic reviews in Toxicology and
2 Environmental health Research (COSTER)

3 **Author List**

4 *Corresponding and first author:* **Paul Whaley**, Lancaster Environment Centre, Lancaster University,
5 Lancaster, LA1 4YQ, UK | p.whaley@lancaster.ac.uk

6 *Other authors:*

7 **Elisa Aiassa**, European Food Safety Authority (EFSA), Assessment and Methodological Support unit.
8 Via Carlo Magno 1/A, 43126 Parma, Italy | elisa.aiassa@efsa.europa.eu

9 **Claire Beausoleil**, ANSES (French Agency for Food, Environmental and Occupational Health Safety),
10 Risk Assessment Department, Chemical Substances Assessment Unit, F-94700 Maisons-Alfort, France
11 | claire.beausoleil@anses.fr

12 **Anna Beronius**, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden |
13 anna.beronius@ki.se

14 **Gary Bilotta**, School of Environment and Technology, University of Brighton, Brighton, UK |
15 g.s.bilotta@gmail.com

16 **Alan Boobis** National Heart & Lung Institute, Imperial College London, London, UK |
17 a.boobis@imperial.ac.uk

18 **Rob de Vries**, SYRCLE, Department for Health Evidence, Radboud Institute for Health Sciences,
19 Radboudumc, Nijmegen, The Netherlands | rob.devries@radboudumc.nl

20 **Annika Hanberg**, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden |
21 annika.hanberg@ki.se

22 **Sebastian Hoffmann**, Evidence-based Toxicology Collaboration at Johns Hopkins Bloomberg School
23 of Public Health, Paderborn, Germany | sebastian.hoffmann@seh-cs.com

24 **Neil Hunt**, Yordas Group, Lancaster Environment Centre, Lancaster University, Lancaster, LA1 4YQ,
25 UK | n.hunt@yordasgroup.com

26 **Carol F. Kwiatkowski**, The Endocrine Disruption Exchange. P.O. Box 54, Eckert, CO, 81418, USA |
27 carolkw@tedx.org

28 **Juleen Lam**, University of California, San Francisco and California State University, East Bay. 28500
29 Carlos Bee Blvd Room 502, Hayward, CA 94542, USA | Juleen.Lam@csueb.edu

30 **Steven Lipworth**, Royal Society of Chemistry, Burlington House, Piccadilly, London, W1J 0BA, UK

31 **Olwenn Martin**, Institute for the Environment, Health and Societies, Brunel University London,
32 Uxbridge, UK | olwenn.martin@brunel.ac.uk

33 **Nicola Randall**, Harper Adams University, Newport, Shropshire, UK | nrandall@harper-adams.ac.uk

34 **Lorenz Rhomberg PhD ATS**, Gradient, 20 University Road, Cambridge, MA 02138, USA
35 | lrhomberg@gradientcorp.com

36 **Andrew A. Rooney**, Division of the National Toxicology Program, National Institute of Environmental
37 Health Sciences, North Carolina, USA | andrew.rooney@nih.gov

38 **Holger J. Schünemann**, McGRADE Centre and Michael G De Groote Cochrane Canada Centre, Dept.
39 of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main Street West,
40 Hamilton, ON, Canada | schuneh@mcmaster.ca

41 **Daniele Wikoff**, ToxStrategies, 31 College Place, Suite B118B, Asheville, NC 28801, USA |
42 dwikoff@toxstrategies.com

43 **Taylor Wolffe**, Lancaster Environment Centre, Lancaster University, Lancaster, LA1 4YQ, UK |
44 t.wolffe@lancaster.ac.uk

45 **Crispin Halsall**, Lancaster Environment Centre, Lancaster University, Lancaster, LA1 4YQ, UK |
46 c.halsall@lancaster.ac.uk

47 **Declaration of Interests**

50 Due to the objective of the project being to establish, across a broad selection of
51 stakeholders, a consensus view on sound and good practice in the conduct of environmental
52 health systematic reviews, participants in the process were selected because of their varying
53 interests in the conduct of environmental health research. With regard to the development of
54 COSTER, the authors declare they have no actual or potential competing financial interests, and
55 certify that their freedom to design, conduct, interpret, and publish the research was not
56 compromised by any controlling sponsor. For transparency in interests, each author has
57 completed an International Committee of Medical Journal Editors Form for Disclosure of
58 Potential Conflicts of Interest. These forms are included as supplemental information.

59 **Highlights**

- 60 • COSTER is the first effort at defining a best-practice standard for conduct of systematic
61 reviews in the environmental health sciences
- 62 • COSTER consists of 70 “requirements” for conduct of a systematic review, with each
63 requirement considered to be “sound and good” practice by the consensus group
- 64 • The consensus group consists of systematic review practitioners and related experts
65 from industry, non-government organisations, government agencies and academia
- 66 • COSTER provides a detailed discussion of the role, interpretation and development of
67 standards as they contribute to defining good practice in research
- 68 • COSTER is intended as the first step, not the final word, in defining best practice
69 standards for conduct of environmental health systematic reviews

70

Abstract

Background: There are several standards which make explicit a consensus view on sound practice in systematic reviews (SRs) for the medical sciences. Until now, no equivalent standard has been published for SRs which focus on human health risks posed by exposure to environmental challenges, chemical or otherwise.

Objectives: To develop an expert, cross-sector consensus on a core set of requirements for sound practice in planning and conducting a SR in the environmental health sciences.

Methods: A draft set of requirements was derived from two existing standards for SRs in biomedicine and discussed at an international workshop of 33 participants from government, industry, non-government organisations, and academia. The guidance was revised over six follow-up webinars and several rounds of email feedback, until there was group consensus that a comprehensive framework for the planning and conduct of high-quality environmental health SRs had been articulated.

Results: The Conduct of Systematic Reviews in Toxicology and Environmental Health Research (COSTER) standard is a code of practice consisting of 70 requirements across eight performance domains, representing the consensus view of a diverse group of experts as to what constitutes “sound and good” practice in the conduct of environmental health SRs.

Discussion: COSTER provides a set of sound-practice requirements which, if followed, should facilitate the production of credible, high-value SRs of environmental health evidence. COSTER clarifies sound and good practice in a number of controversial aspects of SR conduct, providing requirements relating to management of conflicts of interest, inclusion of grey literature, and protocol registration and publication. Not all of the practices are yet commonplace, but environmental health SRs would benefit from their introduction. Some aspects of SR, such as assessment of external validity at the level of individual study, are not yet sufficiently developed for consensus on sound practice to be achieved.

1 Introduction

In the fields of toxicology, environmental health and chemical risk assessment (henceforth abbreviated as “environmental health (EH) research”), systematic reviews (SRs) are increasingly being conducted and used by academics, non-government organisations, industry and regulators (Whaley et al. 2016a) to characterise health hazards and risks posed by exposure to environmental challenges. One of the drivers of this growing interest is increasing recognition of how systematic methods offer a potential new benchmark in best practice for aggregating and summarising evidence in support of policy decisions (EFSA 2010; Rooney et al. 2014; NAS 2017, 2014; Stephens et al. 2016).

In service of this interest, there is a growing number of documents which provide varying types of guidance for conducting SRs in EH research. These include: a handbook by the US National Toxicology Program Office of Health Assessment and Translation, first published in 2015 and updated in 2019 (NTP OHAT 2019); guidance documents by the Texas Commission on Environmental Quality (Schaefer and Myers 2017), the European Food Safety Authority (EFSA 2015), and the US Environmental Protection Agency application of SR methods in Toxic Substances Control Act (TSCA) risk evaluations (EPA 2018); the 2019 updates to the Preamble to the International Agency for Research on Cancer Monographs and Instructions to Authors (IARC 2019a, 2019b); the SYRINA framework describing systematic methods for the identification of endocrine disruptors (Vandenberg et al. 2016); and the Navigation Guide framework for environmental health SRs (Woodruff and Sutton 2014).

While these documents offer valuable guidance on conduct of SRs, they differ in their levels of comprehensiveness and detail, domains of applicability, and the extent to which the various practices they describe are either mandatory or optional. For example, the OHAT handbook is for SRs conducted in support of hazard assessment within a US regulatory framework, whereas the Navigation Guide is intended for a more general research context. While the Navigation Guide and OHAT approaches both employ a Cochrane-derived risk of bias approach to appraising study quality (Higgins et al. 2011), SYRINA lays out a wider range of options which an SR team can choose between, and the application of SR methods in TSCA does not follow the NTP-implemented Cochrane guidance to eschew scoring of study quality in assessing risk of bias. None of these documents therefore provide a collectively consistent standard for good practice in the planning and conduct of an EH SR.

The situation in EH research sits in contrast to the biomedical sciences, where standards for conducting and reporting SRs have been proliferating rapidly over the last three decades. The EQUATOR Network’s online *Library for Health Research Reporting* currently lists over 400 standards for reporting health research (<https://www.equator-network.org/library/>). Although

132 many of the listed standards are concerned with reporting of primary research, there are also
133 numerous standards for reporting of SRs, such as the PRISMA checklist for systematic reviews
134 of interventions (Moher et al. 2009) and the MOOSE reporting guidelines for SRs of
135 observational studies in medicine (Stroup et al. 2000). Standards which focus explicitly on the
136 conduct rather than reporting of SRs include the US Institute of Medicine (IOM) *Finding What
137 Works in Health Care (WWHC): Standards for Systematic Reviews* (Eden et al. 2011) and the
138 Cochrane Editorial Unit's *Methodological Expectations for Conduct of Intervention Reviews*
139 (MECIR) standard (Chandler et al. 2013) recently updated to version 1.07 in November 2018
140 (Higgins et al. 2018).

141 Standards are distinguished from guidelines and handbooks in that, in the form of a list of
142 requirements, they “provide a set of agreed principles or criteria for a product, service or
143 practice, such that users of those products can make reliable assumptions about their
144 performance, safety, compatibility and/or other features as specified in the standard” (British
145 Standards Institution 2016b). Standards vary in detail and prescriptiveness according to the
146 function they perform, from “specifications” which set out detailed, absolute requirements, to
147 flexible “codes of practice” which recommend “sound and good practice as currently undertaken
148 by competent and conscientious practitioners” (British Standards Institution 2016a). Standards
149 are always voluntary (except when laws and regulations refer to them and make them
150 compulsory) but allow a benchmark to be set, against which the quality of a product can be
151 evaluated. The development and promulgation of standards which provide clear, expert
152 guidance on good practice are considered to be an important contributor to ensuring the quality
153 of SRs (Eden et al. 2011).

154 While the universal nature of the fundamentals of SR methods should result in broad overlap
155 in sound SR practices between biomedical and EH research, the potential for cultural and
156 research-specific differences between the domains mean that direct applicability of biomedical
157 SR standards to EH research cannot be assumed (Haddaway et al. 2018a). These differences
158 include the types of evidence being summarised (with a focus in EH on observational human,
159 experimental animal and *in vitro* study designs intended to elucidate disease aetiology and
160 identify health risks, as opposed to a prevalence of methods for identifying effective treatments
161 for disease using a body of evidence in which randomised controlled trials in humans tends to
162 be more readily available), the types of decision potentially being supported by SRs (e.g.
163 defining the conditions for acceptable use of chemical substances rather than informing
164 healthcare intervention decisions), and specific methodological challenges in evidence synthesis
165 (e.g. the need in EH research to integrate evidence from human, animal, *in vitro*, and *in silico*

166 studies). These differences mean that standards developed in biomedicine need to be
167 methodically assessed, and potentially adapted and added to, by EH research practitioners.

168 A broad cross-section of EH expert stakeholders was therefore convened with the objective
169 of adapting biomedical SR standards to the EH domain. The aim was to establish participating
170 stakeholder consensus on a core set of requirements which describe the sound and good
171 practices in the conduct of SRs in EH, which, if adhered to, will improve the quality of SR
172 projects.

173 **2 Methods**

174 A workshop was held 2 December 2016, attended by 33 expert participants selected to cover
175 academic, policy, regulatory, non-government and industry sectors (see Supplemental
176 Information 01). Participants all had at least some experience in evidence synthesis, with an
177 overall balance of expertise in SR methods, weight-of-evidence methods, chemical risk
178 assessment, toxicology, environmental health research and chemicals policy being sought
179 across the group. “Consensus” was defined following International Organization for
180 Standardization (ISO) terminology as “general agreement, characterized by the absence of
181 sustained opposition to substantial issues by any important part of the concerned interests and
182 by a process that involves seeking to take into account the views of all parties concerned and to
183 reconcile any conflicting arguments” (ISO/IEC 2004).

184 Development of the standard was seeded by two discussion draft documents (see
185 Supplemental Information 02 and 03) developed by PW, presenting a draft standard derived
186 from version 2.3 of the Cochrane *MECIR* standards (Chandler et al. 2013) and the US Institute of
187 Medicine *WWHC: Standards for Systematic Reviews* (Eden et al. 2011). These standards were
188 taken to already represent a high degree of consensus and expectation of effectiveness of sound-
189 practice requirements relating to general SR methods in biomedicine, providing a solid basis for
190 a standard for SRs in EH research. The discussion draft also outlined for participants the
191 potential role of standards in quality management of research, explained how standards are
192 developed, and described how the workshop and subsequent follow-up activities would be
193 structured to facilitate consensus on a standard for conduct of SRs in EH research.

194 The draft standard was discussed requirement-by-requirement at the workshop by two
195 break-out groups working in parallel, chaired by PW and JL. Input was solicited on the
196 following: (a) which of the proposed criteria should be included in a code of practice for SRs in
197 toxicology and chemical risk assessment; (b) if and how the included criteria should be

198 reformulated; (c) whether there were any additional criteria which should be included, and if
199 so, how they should be formulated; and (d) questions for clarification and follow-up.

200 GB and CH took notes of the discussion. Comments were collated into a redrafted document
201 and cross-checked by PW against the Campbell Collaboration *MEC2IR* standard (Campbell
202 Collaboration 2014). This was to check for any further possible requirements, as suggested in
203 discussion at the workshop. The redrafted requirements were then discussed in a series of six
204 one-hour webinars held between January and June 2017, chaired by PW, and attended on
205 average by six participants (EA, ABe, RdV, KG, AH, NH, SH, CK, JL, OM, LR, AR, HS, KS, DW, CH,
206 TW participated in at least one). The webinars were followed by email exchanges and bilateral
207 phone calls between PW and various authors to finalise wording and agree that consensus had
208 been reached.

209 The consensus process was closed by PW on 24 January 2018; participating authors
210 confirmed agreement with the consensus by signing off as co-authors of this manuscript.
211 Participants in the process who contributed to the workshop and related discussions but were
212 not able to sign off on the manuscript have been listed in the Acknowledgements.

213 **3 Results**

214 COSTER is a standard for design and conduct of SRs in environmental health research. It
215 consists of 70 requirements divided across 8 domains. The domains cover: planning the SR;
216 searching for evidence; selecting evidence for review; extracting data; critically appraising each
217 individual included study; synthesising the evidence; interpreting the evidence and
218 summarising what it means for the review question; and drawing conclusions (see Figure 1).

219 The number of requirements in each domain is a function of the number of decisions which
220 need to be made at each stage of planning and conducting a SR, combined with whether or not
221 consensus among the authors on sound practice relating to each decision-point was attainable.
222 The requirements are listed in Table 1. Guidance on how to use COSTER is provided in the
223 Discussion section below.

224 There was no consensus view in the group on the extent to which any individual requirement
225 should be described as compulsory, desirable, or merely discretionary: while all requirements
226 are considered by the authors to constitute sound practice, the authors did not believe it was
227 possible to make general claims about the relative necessity of any single requirement across
228 the wide variety of contexts in which EH SRs are conducted.

229 Readers should note that the term “requirement” is used in its technical sense as a provision
 230 within a standard, not in the broader sense of something being compulsory.

231

COSTER v1.0.0: Requirements for sound and good practice in the planning and conduct of environmental health systematic reviews
1. Planning the Review and Preparing the Protocol
1.1 Securing capacity, competencies and tools
1.1.1 Ensure the review team has sufficient combined competence to conduct the systematic review, including relevant expertise in: information science (for e.g. search strategies); evidence appraisal; statistical methods; domain or subject expertise; systematic review methods.
1.1.2 Identify information management practices for each stage of the review, including reference and knowledge management tools, systematic review software, and statistics packages.
1.1.3 Exclude people or organisations with apparent conflicts of interest relating to the findings of the review from analysis and decision-making roles in the review process.
1.1.4 Disclose the roles and all potential conflicts of interest of all people and organisations involved in planning and conducting the review, including all providers of financial and in-kind support.
1.2 Setting the research question to inform the scope of the review (“problem formulation”)
1.2.1 Demonstrate the need for a new review in the context of the scientific value of the question, the importance to stakeholders of the question being asked, and the findings of any pre-existing primary research and/or evidence syntheses.
1.2.2 Articulate the scientific rationale for each question via development of a theoretical framework which connects e.g. the exposure to the outcomes of interest (or otherwise as appropriate given the objectives of the review).
1.2.3 For each research question to be answered by the review, prospectively define a statement of the research objective in terms of one or more of the following components, selected as appropriate: <ul style="list-style-type: none"> • Population (objects of investigation, i.e. the entities to which exposures or interventions happen) • Exposure or Intervention (the administered change in conditions of the objects of investigation, to include timing, duration and dose) • Comparator (the group to which the intervention or exposure groups are being compared) • Outcome (the change being measured in the intervention or exposure group) • Study design (specific design features of relevant research) • Target condition (the object of a test method for diagnosis or detection)
1.3 Defining eligibility criteria
1.3.1 Define and justify unambiguous and appropriate eligibility criteria for each component of the objective statement.
1.3.2 Define the points at which screening for eligibility will take place (e.g. pre-screening based on title/abstract, full text screening, or both)
1.3.3 For interventions, exposures and comparators: define as relevant to review objectives the eligible types of interventions and/or exposures, methods for measuring exposures, the timing of

the interventions/exposures, and the interventions/exposures against which these are to be compared.
1.3.4 For outcomes: define as relevant to review objectives the primary and secondary outcomes of interest (including defining which are apical and which are intermediate), what will be acceptable outcome measures (e.g. diagnostic criteria, scales) and the timing of the outcome measurement.
1.3.5 For study designs: define eligible study designs per design features rather than design labels.
1.3.6 Include all relevant, publicly-available evidence, except for research for which there is insufficient methodological information to allow appraisal of internal validity.
1.3.7 Include evidence which is relevant to review objectives irrespective of whether its results are in a usable form.
1.3.8 Include relevant evidence irrespective of language.
1.3.9 Exclude evidence which is not publicly available.
1.4 Planning the review methods at protocol stage
1.4.1 Design sufficiently sensitive search criteria, so that studies which meet the eligibility criteria of the review are not inadvertently excluded.
1.4.2 Design “characteristics of included studies” table.
1.4.3 Define the risk of bias assessment methods to be used for evaluating the internal validity of the included research. If observational studies are included, this should cover identification of plausible confounders.
1.4.4 Design the methods for synthesising the included studies, to cover: qualitative and quantitative methods (with full consideration given to synthesis methods to be used when meta-analysis is not possible); assessment of heterogeneity; choice of effect measure (e.g. RR, OR etc.); methods for meta-analysis and other quantitative synthesis; pre-defined, appropriate effect modifiers for sub-group analyses.
1.4.5 Define the methods for determining how, given strengths and limitations of the overall body of evidence, confidence in the results of the synthesis of the evidence for each outcome is to be captured and expressed. (For reviews which include multiple streams of evidence, this may need to be defined for each stream.)
1.4.6 For reviews which include multiple streams of evidence (e.g. animal and human studies), define the methods for integrating the individual streams into an overall result. This should include a description of the relative relevance of populations (e.g. species, age, comorbidities etc.), exposures (e.g. timing, dose), and outcomes (direct or surrogate, acute or chronic model of disease, etc.), as appropriate, per which inferences about predicted effects in target populations can be made from observed effects in study populations.
1.4.7 Pilot-test all components of the review process in which reviewer performance could affect review outcomes. This includes the design and usability of the data extraction form/s, and the conduct of the risk of bias assessment.
1.5 Publishing the protocol
1.5.1 Create a permanent public record of intent to conduct the review (e.g. by registering the protocol in an appropriate registry) prior to conducting the literature search.
1.5.2 As appropriate for review planning and question formulation, secure peer-review and public feedback on a draft version of the protocol, incorporating comments into the final version of the protocol.

1.5.3 Publish the final version of the protocol in a public archive, prior to screening studies for inclusion in the review.
1.5.4 Clearly indicate in the protocol and review report any changes in methods made after testing or conduct of any steps of the review.
2. Searching for Evidence
2.1 Search all the key scientific databases for the topic, including national, regional and subject-specific databases.
2.2 Define reproducible strategies for identifying and searching sources of grey literature (databases, websites etc.).
2.3 Structure search strategies for each database, electronic and other source, using appropriate controlled vocabulary, free-text terms and logical operators in a manner which prioritises sensitivity.
2.4 Search within the reference lists of included studies and other reviews relevant to the topic ("hand-searching") and consider searching in the reference lists of documents which have cited included studies.
2.5 Search by contacting relevant individuals and organisations.
2.6 Document the search methods and results in sufficient detail to render them transparent and reproducible.
2.7 Re-run all searches and screen the results for potentially eligible studies within 12 months prior to publication of the review (screening at least at the level of title plus abstract). In deciding whether to incorporate new studies in the review, the importance of a possible change in results should be weighed against any delay in publication. Potentially eligible studies which have not been incorporated should be listed as "awaiting classification".
3. Screening Evidence for Inclusion
3.1 Screening of each piece of evidence for inclusion to be conducted by at least two people working independently, with an appropriate process (e.g. third-party arbitration) for identifying and settling disputes.
3.2 Document decisions in enough detail to allow presentation of the results of the screening process in a PRISMA flow chart.
3.3 Studies which are excluded after assessment of full text should be listed in a table of excluded studies along with the reason for their exclusion (one reason is sufficient).
3.4 Do not exclude multiple reports of the same research (e.g. multiple publications, conference abstracts etc.); instead collate the methodological information from each of the reports as part of the data extraction process for each unit of evidence.
4. Extracting Relevant Data from Included Study Reports
4.1 Collect characteristics of the included studies in sufficient detail to populate the planned "characteristics of included studies" table.
4.2 Extraction of study characteristics and outcome data to be conducted by at least two people working independently with an appropriate process (e.g. third-party arbitration) for identifying and settling disputes.
4.3 Assessment of risk of bias to be conducted separately from data extraction. Ideally, and where appropriate, risk of bias assessment should be conducted between extraction of study characteristics and extraction of outcome data (study results).

4.4 Correct for errors and omissions in data reported in included studies by: (1) collecting the most detailed numeric data possible; (2) examining relevant retraction statements and errata for information; (3) obtaining where possible relevant unpublished data which is missing from reports and studies.
4.5 Check accuracy of the numeric data in the meta-analysis utilising an appropriate process (e.g. third-party control).
5. Appraising the Internal Validity of Included Studies
5.1 Appraise internal validity of each included study via the risk of bias assessment methodology specified in the protocol.
5.2 Assess risk of bias per outcome or outcome-exposure pair (as appropriate) rather than per study.
5.3 Risk of bias assessment is to be conducted by at least two people working independently, with an appropriate process (e.g. third-party arbitration) for identifying and settling disputes.
5.4 Apply the risk of bias assessment tool thoroughly and consistently to each included study, recording each risk of bias judgement made by each reviewer, and any disagreements and how they were resolved.
5.5 If there is empirical evidence which supports a judgement, comment but do not guess on likely direction and (if possible) magnitude of effect of bias.
5.6 Provide appropriate explanation for judgement of risk of bias, making reference to decision processes described in the protocol, and using supporting quotes from study reports or noting if information was not available.
6. Synthesising the Evidence / Deriving Summary Results
6.1 Undertake (or display) meta-analyses only when studies are sufficiently comparable as to render the combined result meaningful.
6.2 Transform all scales (where appropriate) into common measures of outcome, explaining how each scale has been reinterpreted in the review.
6.3 Use appropriate methods to assess the presence and extent of between-study variation (statistical heterogeneity) when undertaking a meta-analysis.
6.4 If important statistical heterogeneity is observed, explain how this is accommodated in developing appropriate summary results for the review (e.g. by not pooling at all, by conducting subgroup analyses etc.)
6.5 Assess the potential for publication bias in the data (i.e. systematic differences between the evidence which was accessible to the review, and the evidence which was not).
6.6 Assess potential impact of risk of bias in the synthesis, based on the results of the appraisal of risk of bias in the included studies (e.g. sub-group analysis excluding studies at high risk of bias; appropriate qualitative or quantitative approaches).
6.7 Test the robustness of the results using sensitivity analyses (such as the impact of notable assumptions, imputed data, borderline decisions and studies at high risk of bias).
6.8 If subgroup analyses are conducted, follow the subgroup analysis plan specified in the protocol, avoiding over-interpretation of any particular findings; sensible post-hoc analyses may also be carried out.
7. Interpreting Results

7.1 Interpret the internal validity of the overall body of evidence by considering results of the appraisal of internal validity (risk of bias) of each included study. The review should describe the potential for biased summary results due to limitations in study design and conduct (e.g. extent of randomisation, blinding, confounding etc.) and the implications of these limitations for drawing conclusions based on the overall body of evidence.
7.2 Interpret the consistency of the overall body of evidence, accounting for explainable and unexplainable variation between studies. If a meta-analysis has been conducted, consider statistical heterogeneity. Where appropriate, conduct sub-group and sensitivity analyses.
7.3 Interpret any subgroup analyses without selective reporting of results or placing undue emphasis on specific findings.
7.4 Interpret the precision of the results of any syntheses, taking care to interpret statistically non-significant results as findings of uncertainty rather than no effect, unless the confidence intervals are sufficiently narrow to rule out an important magnitude of effect.
7.5 Interpret the magnitude of the observed effect.
7.6 Interpret the dose-response relationship in the observed results.
7.7 Interpret the potential effects of reporting and publication biases (e.g. unreported outcome data, unpublished studies etc.) on the observed results.
7.8 Interpret the external validity of the overall body of evidence. Any inferences or predictions about effects in target populations which are made based on effects observed in the populations in the included studies should accord with the considerations defined in the protocol about the relative relevance of populations (e.g. species, age, comorbidities etc.), exposures (e.g. timing, dose), and outcomes (direct or surrogate, acute or chronic model of disease, etc.), as appropriate. Deviations from these considerations must be explained and justified.
7.9 Include the “summary of findings” table.
7.10 Summarise the quality of the overall body of evidence into an appropriate overall statement of confidence in the results of the synthesis.
8: Drawing Conclusions
8.1 Draw out implications based only on findings from the synthesis of studies included in the review.
8.2 Describe implications for research based on Population-Exposure-Comparator-Outcome or other appropriate formula consistent with that specified in the research objective.
8.3 Avoid describing policy implications in terms of specific actions authors feel that decision-makers should take. If authors feel it is necessary to describe policy implications, articulate them in terms of hypothetical scenarios rather than making specific policy recommendations.

Table 1: COSTER requirements for sound practice in the planning and conduct of environmental health systematic reviews. Table 1 should be read alongside Table 2, which serves as an explanation and elucidation of a number of the requirements of COSTER.

4 Discussion

4.1 How to use COSTER

4.1.1 The role of COSTER in ensuring high-quality EH SRs

COSTER is intended to help research teams ensure that a SR has the following three characteristics:

1. is useful, addressing an important research question, and advancing community understanding of an environmental health issue via a methodology of synthesising existing research;
2. is transparent, encouraging comprehensive consideration of the assumptions and methods employed in a SR such that, if they are adequately reported, a reader is able to appraise the validity of the SR's findings and assess their relevance to a given decision-making context;
3. is credible, minimising the risk that its findings are biased either by limitations in the evidence base itself or in the processes used to locate and synthesise that evidence.

The application of COSTER is best considered in the context of a broader quality management process that is facilitated by reference to three types of document:

- a. standards for conduct of research, which describe the core requirements for carrying out a sound and good piece of research;
- b. standards for reporting of research, which describe the key information which needs to be presented to a reader in order that its quality can be evaluated;
- c. critical appraisal tools, which help a reader analyse project documentation to determine the quality of a reported piece of research.

COSTER is intended to contribute to (a) above, offering guidance on best practice in conduct of SRs in the form of a list of requirements. COSTER has been designed neither as a reporting standard nor as a critical appraisal tool; rather, it is conceived as a tool or recipe for helping researchers plan and conduct robust systematic reviews, by making explicit a set of practices which a group of experts have agreed on as being sound and good. While it identifies requirements for sound practice in conduct of a EH SR, and could therefore inform the development of reporting standards and critical appraisal tools, it has not been developed or tested for effectiveness in helping researchers report their SR, nor readers appraise a SR, and should not be used for either purpose without appropriate adaptation.

263 COSTER is intended to be usable by any entity with a stake in the quality of conduct of an EH
264 SR project. This could include: journals which might require SR submissions to comply with
265 some or all of the COSTER requirements; research teams wishing to conduct a SR; research
266 commissioners seeking confidence that a contractor will conduct a sound and good SR project;
267 quality assurance units in research-associated organisations seeking to implement consistent,
268 sound and good SR practices; or government agencies and scientists seeking to demonstrate
269 compliance with an agreed set of practices for conduct of research in a regulatory setting. In
270 conjunction with appropriate appraisal tools and reporting guidelines, thoughtful use of
271 COSTER should increase the likelihood that a SR project is successful.

272 *4.1.2 Managing the number of requirements in COSTER*

273 While 70 may seem like a large number of requirements for a research team to fulfil, SRs are
274 complex, multi-disciplinary projects which typically take 12-36 months to complete (Borah et al.
275 2017; Haddaway and Westgate 2019). Although numbers are not directly comparable because
276 of differences in how the requirements of each stage of a review are presented, COSTER is
277 comparable in size to WWHC, which consists of 82 requirements across 4 domains, and MECIR
278 1.07, which consists of 75 requirements across 10 domains (Higgins et al. 2018).

279 The COSTER requirements are designed to be addressed in parallel to the development,
280 conduct, and reporting of a systematic review in an iterative manner which mirrors many of the
281 considerations that should naturally arise for research teams undertaking each of these steps.
282 Therefore, the fulfilment of these requirements is anticipated to be already addressed or
283 incorporated in a well-designed and well-conducted SR and would not constitute an additional
284 burden in these scenarios. On the other hand, these requirements should help identify
285 oversights and limitations in design and conduct that could undermine the integrity of a SR
286 project which, if corrected, should increase the quality of the resulting product and ideally be
287 worth the additional effort.

288 *4.1.3 How should compliance with COSTER be described?*

289 When research teams report the use of COSTER in planning and conducting a SR, they are
290 encouraged to avoid broad summary statements such as “the COSTER code of practice was
291 followed”. Although prevalent in the literature, such self-reported statements are usually only
292 partly true and may therefore mislead the reader about the exact methods used (Page and
293 Moher 2017). Instead, authors should report that COSTER was used to inform the planning and
294 conduct of a SR, and transparently describe whether and how they were able to fulfil each
295 requirement. Since COSTER is not itself a reporting standard, this process may be facilitated by
296 use of SR reporting standards such as PRISMA (Moher et al. 2009), ROSES (Haddaway et al.
297 2018b), or MOOSE (Stroup et al. 2000). We recommend that COSTER-specific extensions of such

298 tools be developed, to address any potential inconsistencies between the reporting standards
299 and the requirements of COSTER.

300 4.1.4 *To what extent are the COSTER requirements compulsory?*

301 Because the COSTER consensus process captures the collective views of a relatively small
302 group of expert (though representative) practitioners, and eschews language which would
303 distinguish between requirements which are compulsory and those which are optional, it is
304 roughly equivalent to the “code of practice” sub-category of standard. A code of practice is
305 defined by the British Standards Institution (BSI) as a comprehensive set of requirements which
306 “reflects current good practice ... as employed by competent and conscientious practitioners”
307 (British Standards Institution 2016a). As such, COSTER is intended to provide an authoritative
308 and comprehensive set of instructions on how to conduct SRs in EH research, while
309 acknowledging that a broader consensus-building and best-practice research process should
310 lead to further development of the standard in future (see section 4.3 for further discussion).

311 What it means to be compliant with COSTER requires some clarification, as the role which
312 standards have in defining good practice is not necessarily intuitive. Five related considerations
313 inform the issue of COSTER compliance.

314 The first consideration is that COSTER does not specify requirements for every step of a SR
315 process. This is because COSTER is only the set of requirements on which the authors could
316 agree, and not the full set of requirements for a complete SR process. One important reason for
317 this discrepancy is that, while some steps of SR are believed to be important, it may not be the
318 case that debate on appropriate methods for those steps is sufficiently settled for a consensus
319 view of best practice to emerge. This was the case for assessment of external validity of
320 individual included studies: while it was proposed as a domain in the pre-workshop discussion
321 draft of COSTER (see Supplemental Materials), no consensus could be reached on requirements
322 for this element of SR. Where COSTER specifies no requirements, as a standard it can obviously
323 be exceeded.

324 The second consideration is that COSTER can be exceeded even where it does specify
325 requirements. This is because the consensus process captures what participants can agree on as
326 being “sound and good” practice, not what counts as exceptional practice. In that sense, COSTER
327 presents a minimum set of requirements which, if a SR were to comply with them, would be
328 likely to provide a satisfactory result. It does not mean that COSTER cannot or should not be
329 exceeded – not only in areas not covered by COSTER (such as assessment of external validity),
330 but also in areas where availability of resource may allow e.g. extremely sensitive searches over
331 multiple databases to be conducted, large numbers of experts to be engaged in refining tools for

332 assessing risk of bias, etc. The more that SR authors are able to exceed the requirements of
333 COSTER, the closer the final SR will be to being exceptional rather than simply sound and good.

334 The third consideration is that, while COSTER describes what needs to be done in order for a
335 EH SR to be COSTER compliant, it does not describe the conditions under which COSTER should
336 be used in a SR project. Nor does it describe how a requirement should be met. The intent of
337 standards is to generate a shared understanding of basic good practice and provide a
338 benchmark against which the quality of a process or product can be assured. Standards are
339 voluntary (although laws and regulations may make reference to standards, and therefore make
340 compliance with them compulsory). While COSTER, as a standard, provides such a benchmark
341 for good practice, the issue of when any given research project, group, agency, journal or other
342 party should adopt COSTER as their standard of practice is a matter for those parties
343 themselves, not one which can be made for them by COSTER or its authors.

344 The fourth consideration is that highly-developed, formal standards utilise language such as
345 “must”, “should” and “may” to communicate differences in importance of a requirement (such as
346 when a requirement is fundamental to a process vs. when it might differentiate sound practice
347 from exceptional practice). COSTER eschews this language as the consensus process did not
348 extend to making such differentiations. As such, all the requirements of COSTER have equal
349 standing – even though each requirement may not be of equal importance to the final quality of
350 a EH SR. This is a limitation which can only be addressed by further development over time of
351 the consensus view of sound and good practice in EH SRs. This also renders important the
352 careful reporting of the extent to which a given SR has complied with the requirements of
353 COSTER, as discussed in section 4.3 above.

354 Fifthly, given the above considerations, it can be anticipated that there will be circumstances
355 in which a user may wish to be only partially compliant with COSTER. These could include
356 situations where, although a project can still usefully be informed by the COSTER requirements,
357 there might be e.g. severe time constraints limiting the methodological rigour achievable by a
358 team of researchers; or when users disagree with the consensus view of COSTER, or find it non-
359 applicable given specific research goals or project context. In such cases, users of COSTER
360 should be explicit about which requirements were not followed and the reasons for so doing,
361 thereby employing COSTER as a benchmark for making transparent the necessary compromises
362 in a particular EH SR project. While deliberate non-compliance should be approached with
363 caution, due to COSTER representing a consensus view of sound and good practices in the
364 conduct of a SR, using COSTER as a framework for making transparent and justifying necessary
365 deviations in methods would be a constructive use of the standard.

366 It may be that full compliance with COSTER is rare and its use as a planning tool and practice
367 benchmark becomes the predominant application of COSTER.

368 To summarise:

- 369 • COSTER does not cover every step of the SR process, only the steps on which
370 consensus about sound and good practice could be agreed.
- 371 • COSTER can be exceeded: compliance is about meeting or exceeding the base
372 requirements. Decisions about how to comply with a COSTER requirement, or
373 whether any given processes are equivalent to so doing, are made at the discretion of
374 the user.
- 375 • A decision to comply with COSTER is voluntary. The full set of requirements of
376 COSTER are compulsory only insofar as full compliance with COSTER is the objective
377 of a SR team.
- 378 • There may be good reasons for selective compliance with the COSTER requirements
379 but this should be approached cautiously and explained to the reader.
- 380 • EH SR projects which are selectively compliant with COSTER, or use alternative
381 methods which the user believes are equivalent to a requirement, are recommended
382 to use COSTER as a benchmark for making transparent their methods.

383 **4.2 Comparing COSTER to other SR standards**

384 Because SR practices are relatively universal and independent of topic, there is substantial
385 overlap between COSTER and other standards, including MECIR and WWHC. However, COSTER
386 is the first explicit effort by EH research practitioners to validate for their particular cultural and
387 research context SR standards which are being applied in biomedicine, bringing together
388 multiple stakeholders with differing views of good practice in EH SR to establish a common
389 consensus view which can be expressed in a set of requirements. By doing this, COSTER
390 contributes to resolving the question of which standards in the conduct of biomedical SRs can
391 be applied to EH research. COSTER also provides a platform on which SR standards for
392 environmental health research can be further developed, particularly in areas where the
393 COSTER process has identified methodological guidance as being needed but immediate
394 consensus on sound and good practice is elusive. In particular, this applies to assessing the
395 external validity of included studies.

396 Table 2 highlights key explanatory points for COSTER according to themes we believe are
 397 either unique to the context of EH research, address aspects of conduct of a systematic review
 398 for which it has historically been difficult in any field to achieve consensus on best practice, or
 399 we believe are a novel contribution to progressing SR standards in general.

Table 2: Key contributions and differences between COSTER and other SR standards, and explanation of significant COSTER requirements	
Requirements	1.1.1 through 1.5.4
Theme	Project planning
Contribution of COSTER	Emphasis on importance of practices in biomedical SRs for environmental health research
<p>Explanation: It is not yet common practice for EH SRs to be conducted according to pre-published protocols, though has been changing since the date of the workshop – see e.g. (Mandrioli et al. 2018; Matta et al. 2019; Hansen et al. 2019). Protocol publication has value for reducing risk that changes in methods mid-project will bias the results of a SR, while also providing an opportunity for external peer-review and early identification of errors which, if left unresolved, could seriously undermine the validity of a resource-intensive project which can take years to conduct (Munafò et al. 2017). COSTER follows MECIR and WWHC in providing detailed guidance on conduct of the planning and protocol phase of a SR, to help research teams avoid potentially costly errors and maximise the value of the project outcomes.</p>	
Requirements	1.1.3, 1.1.4
Theme	Disclosure and management of interests
Contribution of COSTER	Distinction between potential and apparent conflicts of interest to rationale for team selection in SRs
<p>Explanation: COSTER follows Columbia University’s “Responsible Conduct of Research” definition of a conflict of interest (COI) as “a situation in which financial or other personal considerations would be considered by a reasonable person to have the potential to compromise or bias professional judgment and objectivity” (Columbia University 2004). In the Columbia University (2004) framework, “apparent” conflicts of interest are defined as situations “in which a reasonable person would think that the professional’s judgment is likely to be compromised”, while “potential” conflicts of interest are situations “that may develop into an actual conflict of interest” (the reader should note that the framework provides a number of useful illustrative examples). These may be financial and/or non-</p>	

financial. Similar to WWHC, COSTER recognises that any potential COI can, in the right circumstances, become an apparent COI and that all potential COIs should be declared and managed. COSTER distinguishes itself from the WWHC approach to COIs by emphasising that individuals with apparent conflicts of interest need only be excluded from analysis and decision-making roles in the review process. This leaves open the possibility of their involvement as individuals with special knowledge on which review teams can draw, while insulating the review process from risk of bias by prohibiting their involvement in decision-making. This is to allow environmental health SRs to utilise the full range of expertise of a field in which a large body of knowledge is contributed by special interest groups, and therefore many practitioners have apparent COIs.

The intent of these provisions is not to limit participation by excluding participants with affiliation to broad sectors (academic grant holders, industry, or NGOs), but rather to make such associations transparent while focusing the limitations on decision-making roles by those with direct, topic-specific conflicts. In lieu of purpose-built declaration of interest forms for environmental health research, SR authors could consider using forms such as those published by the International Committee of Medical Journal Editors (International Committee of Medical Journal Editors 2013).

Requirements	1.2.2, 1.4.6, 7.8
Theme	Interpreting external validity of the evidence, and integrating multiple evidence streams
Contribution of COSTER	Adaptation of biomedical SR standards to specific context of EH research

Explanation: Operationalising the interpretation of the value of non-human and *in vitro* evidence for understanding potential human health risks from environmental exposures remains a fundamental challenge in adapting SR methods to environmental health. For healthcare interventions, WWHC specifies the use of an “analytical framework which clearly lays out the chain of logic that links the health intervention to the outcomes of interest”. COSTER applies this concept to the assessment of the external validity of evidence, to account for the importance in environmental health research of consistent, unbiased interpretation of an evidence base which is often indirect. Environmental health researchers are increasingly interested in how indirect mechanistic evidence can be organised in predictive networks (Villeneuve et al. 2014a, 2014b) or Key Characteristics frameworks (Smith et al. 2016; Arzuaga et al. 2019; Luderer et al. 2019) to help anticipate whether an environmental challenge will cause an adverse health outcome. In anticipation of the development of

systematic approaches to developing and assessing the plausibility of such networks or framework analyses, in requirement 1.2.2 COSTER requires that authors offer the basic elements of a theoretical framework for interpreting the external validity of included studies as part of the protocol. The framework should describe why and to what extent different populations (e.g. species, developmental stage), exposures (e.g. timing, dose, similarity of substance / read-across) and outcomes (e.g. apical, intermediate) will be considered by the reviewers to be comparable to the target populations, exposures and outcomes of interest. Provision 7.8 specifies that interpretation of the results of synthesis are made in accordance with this pre-specified framework.

While such inferential frameworks may currently be limited in scope, and there should be caution about overly-prescriptive use which can lead to spurious rejection of true hypotheses as much as spurious acceptance of false ones, the authors believe that the use of such frameworks is important in discouraging ad-hoc analysis of evidence which is vulnerable to expectation bias. COSTER takes an initial step in requiring the application of such frameworks for environmental health SRs.

Requirements	1.2.3, 1.3.3, 1.3.4, 1.3.5, 1.3.9
Theme	Formulation of research objectives
Contribution of COSTER	Formal clarification of use of PECO-style statements in formulating SR objectives in EH research
<p>Explanation: COSTER requires that SR objectives be formulated in an appropriate structured format using appropriate elements of the PECOTS (Population-Exposure/Intervention-Comparator-Outcome-Target Condition-Study Design) mnemonic. While questions around effects of chemical exposures are more common, some environmental health SRs investigate interventions (such as amelioration of the effects of exposures) and this is expressly allowed for in COSTER. COSTER also specifies in detail the specific aspects of the PECOTS elements which should be considered in establishing the objectives of a EH research SR, with elements such as timing of exposure being recognised as a potentially critical issue in reliably identifying health risks of chemical exposure, and a requirement that these be considered and defined as necessary. More specific guidance on good practice in the formulation of PECO statements has been developed since COSTER was finalised (Morgan et al. 2018b).</p>	
Requirements	1.3.6, 1.3.9, 3.4
Theme	Including informally-published or previously unpublished literature

Contribution of COSTER	Provides unambiguous rationale for exclusion of study reports due to insufficient information content
<p>Explanation: The consensus view of the authors is that grey literature should be included in systematic reviews. This is because the relevance of evidence is determined by the SR objectives, not by the publication status of that evidence. The inclusion of grey literature also acts as one safeguard against the influence of publication bias; however, researchers should never assume that the grey literature which can be located will be representative of the grey literature overall. Finally, the authors acknowledge that inclusion of grey literature can be daunting. Therefore, COSTER provides an explicit rationale for where researchers can draw the line on including study reports in a SR.</p> <p>Firstly, in keeping with the SR principle of transparency, COSTER mandates that only publicly-available information about a study is eligible for inclusion (requirement 1.3.9). A SR which brings into the public domain previously inaccessible information, can be the mechanism by which such data becomes publicly accessible and therefore eligible for inclusion. This has happened with SRs from WHO (Mandrioli et al. 2018) and Cochrane (Jefferson et al. 2014). Secondly, to prevent the inclusion in a SR of evidence which is potentially misleading but cannot be identified as such by the reviewers, COSTER mandates exclusion of evidence which does not provide sufficient information for risk of bias to be evaluated (requirement 1.3.6). Thirdly, COSTER defines the included study itself, not documents describing the study, as the unit of evidence (provision 3.4). Therefore, all publicly-accessible study documents including conference abstracts etc. should be gathered and assessed for information content as a whole, before a decision is made to exclude a study in accordance with requirement 1.3.6. This is to ensure that study documents which may contain information of potential relevance to the SR's research objectives are not excluded from the data extraction step of the SR.</p> <p>Many studies – especially epidemiological studies – cannot release detailed information on individual participants owing to privacy concerns and legal mandates. The intent of this requirement in COSTER is not to avoid such studies, but rather to ensure that the uses of study-specific findings within the larger analysis should be supported by those aspects of the underlying data that are available for public scrutiny.</p>	
Requirements	1.5.1, 1.5.2, 1.5.3
Theme	Protocol publication
Contribution of COSTER	Differentiates between protocol registration and publication as distinct steps of the methods development process

Explanation: Protocol registries such as PROSPERO (Centre for Reviews and Dissemination) and pre-print repositories such as Zenodo (CERN) allow authors to register their methods in advance of conducting a SR. In theory, this third-party version control of the registered protocol allows changes in methods to be audited, discouraging bias which can be introduced by ad-hoc decision-making. However, there are no protocol registries which currently require authors to submit sufficient information about methods that a registered protocol can be assumed to be a complete plan for conducting a SR. Nor do such registries have capacity to peer-review protocols for soundness of the proposed methods, at most performing only basic quality control checks. This leads to a situation in which the value of registration for ensuring the comprehensiveness and validity of methods for a given protocol is unclear. Therefore, it is the view of the authors that the current primary value of a registered protocol is a record of intent to conduct a SR, rather than serving as a guarantee of comprehensive documentation of methods prior to conduct of a SR.

COSTER addresses this ambiguity, of the status of registered protocol vs. comprehensive documentation of proposed methods, by specifying that authors of SRs take a two-step approach to protocol publication. As the first step, an outline of the proposed SR with the minimum of necessary information to characterise objectives and approach should be posted on an appropriate public registry or functional equivalent thereof, over which the authors have no direct control (requirement 1.5.1). This first draft is the permanent public record of intent to conduct a systematic review, functioning to communicate research aims and help other review teams avoid planning duplicate SRs. As the second step, this draft can then be developed in further detail as a full protocol, which is submitted to external peer-review or other appropriate quality management process (requirement 1.5.2), and then published either in a scientific journal or a repository (requirement 1.5.3). An example of journal publication of a protocol is provided by (Mandrioli et al. 2018), and in a public repository by (Martin et al. 2018).

Requirements	1.4.3, 5
Theme	Internal validity assessment
Contribution of COSTER	Explicit specification of risk of bias methods for assessing internal validity of included studies

Explanation: To prevent systematic errors in included studies being transmitted through to the findings of a SR, it is necessary that each individual included study be assessed for internal validity, i.e. its potential to have biased results. Hence, COSTER explicitly requires each individual included study to be assessed for risk of bias. COSTER does not state which

instruments should be used by authors to assess risk of bias, leaving it to SR authors to determine which assessment methods are most suited to their research objectives (except, the tool should specifically target risk of bias). COSTER does, however, present a number of requirements around the process of risk of bias assessment to ensure successful implementation of the risk of bias tool, whatever tool is selected. This includes assessing risk of bias per outcome (requirement 5.2) and making sure each judgement is transparent and grounded in the reviewed text (requirement 5.6).

COSTER's requirements for risk of bias assessment (Domain 5) are strongly influenced by the following approaches to study appraisal: the Cochrane approach to risk of bias as articulated by Higgins et al. (2011); the adaption of the Cochrane approach to environmental health SRs by the National Toxicology Program Office of Health Assessment and Translation (Rooney et al. 2014) and the Navigation Guide (Woodruff and Sutton 2014); and the development process (though not the final tool, as COSTER predates the relevant publications) for the Risk Of Bias Instrument for Non-randomized Studies of Exposures (ROBINS-E) approach to assessing risk of bias of non-randomised studies of environmental health research has also been proposed (Morgan et al. 2019b; Morgan et al. 2018a). COSTER is not an endorsement of any particular approach to risk of bias assessment, and it should also be noted that COSTER predates the publication of the ROB2 approach to risk of bias assessment (Sterne et al. 2019).

Requirements	1.4.5, 7.1, 7.2, 7.4, 7.5, 7.6, 7.7, 7.8, 7.10
Theme	Assessment of quality of the overall body of evidence
Contribution of COSTER	Emphasis on evaluation of quality of evidence against pre-specified criteria known to be of importance when assessing certainty in the results of a SR

Explanation: COSTER presents eight characteristics of a body of evidence which should be systematically evaluated in the course of determining how certain are the results of a SR. These apply to interpreting the overall strength of the evidence base, considered as a whole. While the characteristics are derived from those utilised in the GRADE framework (Guyatt et al. 2008; Guyatt et al. 2011), there are no specifications in COSTER regarding how they ought to be interpreted, except that the approach should be described in the protocol. The authors note there is ongoing work by the GRADE Working Group to further develop the GRADE methodology for the environmental health context (Morgan et al. 2016; Morgan et al. 2019a), and that the US NTP OHAT (Rooney et al. 2014) and the Navigation Guide (Woodruff and Sutton 2014) both employ a close interpretation of the GRADE framework in their

approaches to conducting SRs. A systematic approach to assessing the quality of the evidence is important, because readers of a SR need a trustworthy analysis of how much trust they can put in the evidence. A high-quality review of low-quality evidence is still a trustworthy review – even if the review process has shown that the reader cannot put much trust in the evidence itself.

Requirements	8.3
Theme	Making policy recommendations
Contribution of COSTER	Emphasises that recommendations about interventions are often beyond the scope of a SR of health effects from environmental exposures

Explanation: The development of environmental health policy requires accounting for a wide range of issues relating to evidence of health risks, due political process, and the values and preferences of stakeholders affected by the policy. Systematic reviews ask focused questions which typically respond to only one or two of the full set of issues which may need to be accounted for by a decision-maker when developing policy. This is especially true for SRs of health effects of environmental exposures: while they address potential causes of adverse health outcomes (are aetiological), they would not normally also investigate evidence for the effectiveness of interventions to mitigate those adverse outcomes. While identifying threshold limits, which then inform policy decisions, is of course often the core business of this type of SR, COSTER adheres to the principle that conclusions of a SR should not reach beyond the evidence which was included within it. COSTER therefore requires authors to resist answering questions about how best to mitigate the effects of an exposure or achieve a risk threshold when the evidence relating this has not been addressed by the SR.

The authors recognise, however, that SRs characterising adverse outcomes from environmental exposures are often conducted to support policy decisions. COSTER therefore requires that policy implications be presented as hypothetical frameworks, whereby authors can state that if certain conditions obtain, then a given intervention may be effective for mitigating harm. Assumptions about values, other evidence and potential consequences of a decision should be made explicit when describing potential interventions to address an environmental exposure or mitigate health risks arising therefrom.

400

401

4.3 *Future development of COSTER*

402

As a code of practice, COSTER represents the first step in a broader research and consensus-building process which it is hoped will yield a robust, international standard for conduct of

403

404 systematic reviews in environmental health research. Formal standards are typically based on
405 both expectation and empirical evidence that the practices described in the standard contribute
406 to a product or process being fit for purpose, combined with broad acceptance of the practices
407 among the community that is expected to adopt the standard. Since SR methods are still
408 relatively new in environmental health research, it follows that while expectations for what
409 should work can be captured, and the consensus view of small groups of experienced
410 practitioners can be secured, evidence for what is effective practice is not yet available. This is
411 particularly true for areas in which SR methods are not readily portable from the social science
412 and medical contexts to environmental health, or where environmental health researchers face
413 challenges not encountered in other fields.

414 Broad community consensus is also an unrealistic goal when only a small, albeit growing,
415 part of the community is employing SR methods in conducting reviews of evidence. It also needs
416 to be acknowledged that while COSTER represents the consensus view of the authors, other
417 expert groups may disagree with some of the requirements of COSTER. Such disagreement is
418 healthy; in that regard, by making explicit a set of requirements for SR, COSTER serves as a focal
419 point for advancing consensus across groups.

420 As community experience in environmental health SR develops over the next period, the
421 authors suggest that development of COSTER adapt the framework for development of
422 reporting guidelines for health research presented in Moher et al. (2014). This framework
423 emphasises four steps:

- 424 1. a systematic review of existing standards and guidelines;
- 425 2. a systematic review of the prevalence of current research practices;
- 426 3. critical appraisal of existing guidelines and current research practices for completeness,
427 face validity, and construct validity;
- 428 4. a process to determine community consensus on best practices and the criteria for a
429 guideline.

430 Step 1 would result in a larger seed-set of potential requirements than was provided by
431 selecting the MECIR and IOM standards as the basis for the current consensus. However, such a
432 SR would be a significant undertaking, as it requires interpreting the implied standards in
433 several large handbooks, a large number of reporting standards and potentially even individual
434 SR study reports. This is a major challenge for qualitative analysis. Step 2 would provide
435 evidence of what community practices actually are. Steps 1 and 2 provide data for Step 3, being
436 a description of the extent to which current practices are aligned with what are considered

437 “best” practices, providing further empirical evidence for a formal standard. Step 4, as a broad
438 consensus process, would provide a community view of where current practices fall short of
439 expectation or need, or where specific processes might exceed what the community views as
440 strictly necessary for conduct of a robust SR.

441 **5 Conclusion**

442 COSTER presents the consensus view of a group of expert practitioners as to a set of
443 requirements for planning and conducting a sound and good systematic review. The lack of
444 current guidelines for conduct of high quality environmental health SRs, coupled with
445 exponential growth in publication of SRs (Whaley et al. 2016b), justifies the introduction of
446 COSTER as authoritative but intermediate guidance which authors and publishers can use to
447 immediately improve the quality of SRs. If followed, COSTER should significantly increase the
448 likelihood of success and stakeholder acceptance of an environmental health SR project. As a
449 first step in establishing a formal, community-wide standard, it is intended that COSTER be
450 critiqued and improved over time, as part of a wider process which will ultimately yield a
451 definitive description of the requirements for conduct of SRs in environmental health research.

452 *4100 words body text + 5000 words for Standard and explanatory tables*

453 **Acknowledgements**

454 We would like to thank Kate Jones and the Royal Society of Chemistry for hosting the
455 workshop, and Lancaster University Faculty of Science and Technology and Lancaster
456 Environment Centre for providing funding to run the workshop.

457 The authors declare no competing financial interests. Further details on potential COIs have
458 been provided in the DOI forms (see supplemental materials). The views expressed in this paper
459 are those of the authors and do not necessarily reflect the views or policies of their respective
460 employers or organisations.

461 We would also like to thank the following for their contribution to the workshop discussions:
462 Sarah Bull (Royal Society of Chemistry); Richard Brown (World Health Organization); Kurt
463 Straif (ret.) and Kathryn Guyton (International Agency for Research on Cancer); Julian Higgins
464 (University of Bristol); Toby Lasserson (Cochrane Editorial Unit); Jennifer McPartland
465 (Environmental Defense Fund); Sharon Munn (EU Joint Research Centre); Angelika Tritscher
466 (World Health Organization); Christopher Weiss (US National Institute of Environmental Health
467 Sciences). TW did not participate in the workshop but contributed to the consensus
468 development calls and the manuscript.

Publication bibliography

Arzuaga, Xabier; Smith, Martyn T.; Gibbons, Catherine F.; Skakkebæk, Niels E.; Yost, Erin E.; Beverly, Brandiese E. J. et al. (2019): Proposed Key Characteristics of Male Reproductive Toxicants as an Approach for Organizing and Evaluating Mechanistic Evidence in Human Health Hazard Assessments. In *Environmental health perspectives* 127 (6), p. 65001. DOI: 10.1289/EHP5045.

Borah, Rohit; Brown, Andrew W.; Capers, Patrice L.; Kaiser, Kathryn A. (2017): Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. In *BMJ open* 7 (2), e012545. DOI: 10.1136/bmjopen-2016-012545.

British Standards Institution (2016a): Different types of standards. Available online at <http://www.bsigroup.com/en-GB/standards/Information-about-standards/different-types-of-standards/>, updated on 26/10/16.

British Standards Institution (2016b): What is a standard and what does it do? Available online at <http://www.bsigroup.com/en-GB/standards/Information-about-standards/what-is-a-standard/>, checked on 26/10/16.

Campbell Collaboration (2014): Methodological Expectations of Campbell Collaboration Intervention Reviews (MEC2IR), Conduct Standards, version 1.0. Available online at http://www.campbellcollaboration.org/news_/Campbell_adopts_MEC2IR_guidelines.php, checked on 3/8/2017.

Centre for Reviews and Dissemination: PROSPERO: International prospective register of systematic reviews. University of York. Available online at <https://www.crd.york.ac.uk/prospero/>, checked on 7/21/2019.

CERN: Zenodo. European Organization for Nuclear Research. Available online at <https://zenodo.org/>, checked on 7/21/2019.

Chandler, Jackie; Churchill, Rachel; Higgins, Julian; Lasserson, Toby; Tovey, David (2013): Methodological standards for the conduct of new Cochrane Intervention Reviews. Cochrane Editorial Unit.

Columbia University (2004): Responsible Conduct of Research: Conflicts of Interest. Available online at http://ccnmtl.columbia.edu/projects/rcr/rcr_conflicts/foundation/index.html, checked on 1/3/2018.

Eden, Jill; Levit, Laura A.; Berg, Alfred O.; Morton, Sally C. (2011): Finding what works in health care. Standards for systematic reviews. Washington, D.C.: National Academies Press.

503 EFSA (2010): Application of systematic review methodology to food and feed safety
504 assessments to support decision making. In *EFSA Journal* 8 (6), p. 1637. DOI:
505 10.2903/j.efsa.2010.1637.

506 EFSA (2015): Principles and process for dealing with data and evidence in scientific
507 assessments. In *EFSA Journal* 13 (6), p. 4121. DOI: 10.2903/j.efsa.2015.4121.

508 EPA (2018): Application of Systematic Review in TSCA Risk Evaluations. US EPA Office of
509 Chemical Safety and Pollution Prevention (EPA Document # 740-P1-8001). Available online at
510 [https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/application-systematic-](https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/application-systematic-review-tsca-risk-evaluations)
511 [review-tsca-risk-evaluations](https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/application-systematic-review-tsca-risk-evaluations), checked on 5/8/2019.

512 Guyatt, Gordon H.; Oxman, Andrew D.; Schünemann, Holger J.; Tugwell, Peter; Knottnerus,
513 Andre (2011): GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.
514 In *Journal of clinical epidemiology* 64 (4), pp. 380–382. DOI: 10.1016/j.jclinepi.2010.09.011.

515 Guyatt, Gordon H.; Oxman, Andrew D.; Vist, Gunn E.; Kunz, Regina; Falck-Ytter, Yngve;
516 Alonso-Coello, Pablo; Schünemann, Holger J. (2008): GRADE: an emerging consensus on rating
517 quality of evidence and strength of recommendations. In *BMJ (Clinical research ed.)* 336 (7650),
518 pp. 924–926. DOI: 10.1136/bmj.39489.470347.AD.

519 Haddaway, Neal R.; Macura, Biljana; Whaley, Paul; Pullin, Andrew S. (2018a): Response to
520 “Every ROSE has its thorns”. In *Environ Evid* 7 (1), p. 20. DOI: 10.1186/s13750-018-0133-3.

521 Haddaway, Neal R.; Macura, Biljana; Whaley, Paul; Pullin, Andrew S. (2018b): ROSES
522 RepOrting standards for Systematic Evidence Syntheses: pro forma, flow-diagram and
523 descriptive summary of the plan and conduct of environmental systematic reviews and
524 systematic maps. In *Environ Evid* 7 (1), p. 409. DOI: 10.1186/s13750-018-0121-7.

525 Haddaway, Neal R.; Westgate, Martin J. (2019): Predicting the time needed for environmental
526 systematic reviews and systematic maps. In *Conservation biology : the journal of the Society for*
527 *Conservation Biology* 33 (2), pp. 434–443. DOI: 10.1111/cobi.13231.

528 Hansen, Martin Rune Hassan; Jørs, Erik; Sandbæk, Anneli; Kolstad, Henrik Albert;
529 Schullehner, Jörg; Schlünssen, Vivi (2019): Exposure to neuroactive non-organochlorine
530 insecticides, and diabetes mellitus and related metabolic disturbances: Protocol for a systematic
531 review and meta-analysis. In *Environment international* 127, pp. 664–670. DOI:
532 10.1016/j.envint.2019.02.074.

533 Higgins, Julian P. T.; Altman, Douglas G.; Gøtzsche, Peter C.; Jüni, Peter; Moher, David; Oxman,
534 Andrew D. et al. (2011): The Cochrane Collaboration's tool for assessing risk of bias in
535 randomised trials. In *BMJ (Clinical research ed.)* 343, d5928.

536 Higgins, Julian P. T.; Lasserson, Toby; Chandler, Jackie; Tovey, David; Churchill, Rachel
537 (2018): Methodological Expectations of Cochrane Intervention Reviews (MECIR). Version 1.07.
538 Cochrane. Available online at <https://community.cochrane.org/mecir-manual>, updated on
539 November 2018.

540 IARC (2019a): IARC Monographs on the Identification of Carcinogenic Hazards to
541 Humans: Preamble. IARC. Lyon, France.

542 IARC (2019b): Instructions for Authors for the Preparation of Drafts for IARC Monographs,
543 updated on 6/17/2019.

544 International Committee of Medical Journal Editors (2013): ICMJE Form for Disclosure of
545 Potential Conflicts of Interest. Available online at <http://www.icmje.org/conflicts-of-interest/>,
546 checked on 1/3/2018.

547 ISO/IEC (2004): ISO/IEC 2:2004 Standardization and related activities -- General vocabulary.
548 ISO/IEC. Switzerland. Available online at <https://www.iso.org/standard/39976.html>, checked
549 on 7/20/2017.

550 Jefferson, Tom; Jones, Mark A.; Doshi, Peter; Del Mar, Chris B.; Hama, Rokuro; Thompson,
551 Matthew J. et al. (2014): Neuraminidase inhibitors for preventing and treating influenza in
552 healthy adults and children. In *The Cochrane database of systematic reviews* (4), CD008965. DOI:
553 10.1002/14651858.CD008965.pub4.

554 Luderer, Ulrike; Eskenazi, Brenda; Hauser, Russ; Korach, Kenneth S.; McHale, Cliona M.;
555 Moran, Francisco et al. (2019): Proposed Key Characteristics of Female Reproductive Toxicants
556 as an Approach for Organizing and Evaluating Mechanistic Data in Hazard Assessment. In
557 *Environmental health perspectives* 127 (7), p. 75001. DOI: 10.1289/EHP4971.

558 Mandrioli, Daniele; Schlünssen, Vivi; Ádám, Balázs; Cohen, Robert A.; Colosio, Claudio; Chen,
559 Weihong et al. (2018): WHO/ILO work-related burden of disease and injury: Protocol for
560 systematic reviews of occupational exposure to dusts and/or fibres and of the effect of
561 occupational exposure to dusts and/or fibres on pneumoconiosis. In *Environment international*
562 119, pp. 174–185. DOI: 10.1016/j.envint.2018.06.005.

563 Martin, O. V.; Bopp, S.; Ermler, S.; Kienzler, A.; McPhie, J.; Paini, A. et al. (2018): Protocol For A
564 Systematic Review Of Ten Years Of Research On Interactions In Chemical Mixtures Of
565 Environmental Pollutants.

566 Matta, Komodo; Ploteau, Stéphane; Coumoul, Xavier; Koual, Meriem; Le Bizec, Bruno;
567 Antignac, Jean-Philippe; Cano-Sancho, German (2019): Associations between exposure to
568 organochlorine chemicals and endometriosis in experimental studies: A systematic review
569 protocol. In *Environment international* 124, pp. 400–407. DOI: 10.1016/j.envint.2018.12.063.

570 Moher, David; Altman, Douglas G.; Schulz, Kenneth F.; Simera, Iveta (2014): How to Develop a
571 Reporting Guideline. In David Moher, Douglas G. Altman, Kenneth F. Schulz, Iveta Simera,
572 Elizabeth Wager (Eds.): *Guidelines for Reporting Health Research: A User's Manual*. Oxford, UK:
573 John Wiley & Sons, Ltd, pp. 14–21.

574 Moher, David; Liberati, Alessandro; Tetzlaff, Jennifer; Altman, Douglas G. (2009): Preferred
575 reporting items for systematic reviews and meta-analyses: the PRISMA statement. In *Annals of*
576 *internal medicine* 151 (4), p. 264.

577 Morgan, Rebecca L.; Beverly, Brandy; Gherzi, Davina; Schünemann, Holger J.; Rooney,
578 Andrew A.; Whaley, Paul et al. (2019a): GRADE guidelines for environmental and occupational
579 health: A new series of articles in *Environment International*. In *Environment international* 128,
580 pp. 11–12. DOI: 10.1016/j.envint.2019.04.016.

581 Morgan, Rebecca L.; Thayer, Kristina A.; Bero, Lisa; Bruce, Nigel; Falck-Ytter, Yngve; Gherzi,
582 Davina et al. (2016): GRADE: Assessing the quality of evidence in environmental and
583 occupational health. In *Environment international* 92-93, pp. 611–616. DOI:
584 10.1016/j.envint.2016.01.004.

585 Morgan, Rebecca L.; Thayer, Kristina A.; Santesso, Nancy; Holloway, Alison C.; Blain, Robyn;
586 Eftim, Sorina E. et al. (2018a): Evaluation of the risk of bias in non-randomized studies of
587 interventions (ROBINS-I) and the 'target experiment' concept in studies of exposures: Rationale
588 and preliminary instrument development. In *Environment international* 120, pp. 382–387. DOI:
589 10.1016/j.envint.2018.08.018.

590 Morgan, Rebecca L.; Thayer, Kristina A.; Santesso, Nancy; Holloway, Alison C.; Blain, Robyn;
591 Eftim, Sorina E. et al. (2019b): A risk of bias instrument for non-randomized studies of
592 exposures: A users' guide to its application in the context of GRADE. In *Environment*
593 *international* 122, pp. 168–184. DOI: 10.1016/j.envint.2018.11.004.

594 Morgan, Rebecca L.; Whaley, Paul; Thayer, Kristina A.; Schünemann, Holger J. (2018b):
595 Identifying the PECO: A framework for formulating good questions to explore the association of
596 environmental and other exposures with health outcomes. In *Environment international* 121 (Pt
597 1), pp. 1027–1031. DOI: 10.1016/j.envint.2018.07.015.

598 Munafò, Marcus R.; Nosek, Brian A.; Bishop, Dorothy V. M.; Button, Katherine S.; Chambers,
599 Christopher D.; Du Percie Sert, Nathalie et al. (2017): A manifesto for reproducible science. In
600 *Nat Hum Behav* 1 (1), e124. DOI: 10.1038/s41562-016-0021.

601 NAS (2014): Review of EPA's Integrated Risk Information System (IRIS) Process. Washington
602 (DC).

603 NAS (2017): Application of Systematic Review Methods in an Overall Strategy for Evaluating
604 Low-Dose Toxicity from Endocrine Active Chemicals. Washington (DC).

605 NTP OHAT (2019): Handbook for Conducting a Literature-Based Health Assessment Using
606 OHAT Approach for Systematic Review and Evidence Integration. US National Toxicology
607 Program Office of Health Assessment and Translation. Available online at
608 <https://ntp.niehs.nih.gov/pubhealth/hat/review/index-2.html>, checked on 5/8/2019.

609 Page, Matthew J.; Moher, David (2017): Evaluations of the uptake and impact of the Preferred
610 Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions.
611 A scoping review. In *Systematic reviews* 6 (1), p. 263. DOI: 10.1186/s13643-017-0663-8.

612 Rooney, Andrew A.; Boyles, Abee L.; Wolfe, Mary S.; Bucher, John R.; Thayer, Kristina A.
613 (2014): Systematic review and evidence integration for literature-based environmental health
614 science assessments. In *Environmental health perspectives* 122 (7), pp. 711–718. DOI:
615 10.1289/ehp.1307972.

616 Schaefer, Heather R.; Myers, Jessica L. (2017): Guidelines for performing systematic reviews
617 in the development of toxicity factors. In *Regulatory toxicology and pharmacology : RTP* 91,
618 pp. 124–141. DOI: 10.1016/j.yrtph.2017.10.008.

619 Smith, Martyn T.; Guyton, Kathryn Z.; Gibbons, Catherine F.; Fritz, Jason M.; Portier,
620 Christopher J.; Rusyn, Ivan et al. (2016): Key Characteristics of Carcinogens as a Basis for
621 Organizing Data on Mechanisms of Carcinogenesis. In *Environmental health perspectives* 124 (6),
622 pp. 713–721. DOI: 10.1289/ehp.1509912.

623 Stephens, Martin L.; Betts, Kellyn; Beck, Nancy B.; Cogliano, Vincent; Dickersin, Kay;
624 Fitzpatrick, Suzanne et al. (2016): The Emergence of Systematic Review in Toxicology. In
625 *Toxicological Sciences* 152 (1), pp. 10–16. DOI: 10.1093/toxsci/kfw059.

626 Sterne, Jonathan A. C.; Savović, Jelena; Page, Matthew J.; Elbers, Roy G.; Blencowe, Natalie S.;
627 Boutron, Isabelle et al. (2019): RoB 2: a revised tool for assessing risk of bias in randomised
628 trials. In *BMJ (Clinical research ed.)* 366, 14898. DOI: 10.1136/bmj.14898.

629 Stroup, D. F.; Berlin, J. A.; Morton, S. C.; Olkin, I.; Williamson, G. D.; Rennie, D. et al. (2000):
630 Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis
631 Of Observational Studies in Epidemiology (MOOSE) group. In *JAMA* 283 (15), pp. 2008–2012.

632 Vandenberg, Laura N.; Ågerstrand, Marlene; Beronius, Anna; Beausoleil, Claire; Bergman,
633 Åke; Bero, Lisa A. et al. (2016): A proposed framework for the systematic review and integrated
634 assessment (SYRINA) of endocrine disrupting chemicals. In *Environmental health : a global
635 access science source* 15 (1), p. 74. DOI: 10.1186/s12940-016-0156-6.

636 Whaley, Paul; Halsall, Crispin; Agerstrand, Marlene; Aiassa, Elisa; Benford, Diane; Bilotta,
637 Gary et al. (2016a): Implementing systematic review techniques in chemical risk assessment:
638 Challenges, opportunities and recommendations. In *Environment international* 92-93, pp. 556–
639 564. DOI: 10.1016/j.envint.2015.11.002.

640 Whaley, Paul; Letcher, Robert J.; Covaci, Adrian; Alcock, Ruth (2016b): Raising the standard
641 of systematic reviews published in Environment International. In *Environment international*.
642 DOI: 10.1016/j.envint.2016.08.007.

643 Woodruff, Tracey J.; Sutton, Patrice (2014): The Navigation Guide systematic review
644 methodology: a rigorous and transparent method for translating environmental health science
645 into better health outcomes. In *Environmental health perspectives* 122 (10), pp. 1007–1014. DOI:
646 10.1289/ehp.1307175.


647

648

649

6 Figures

650



651

Figure 1: Domains and conceptual structure of COSTER